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Treating head and neck cancer patients with systemic therapy is challenging because
of tumor related, patient related and treatment related factors. In this review, we aim
to summarize the current standard of care in the curative and palliative setting, and
to describe best practice with regard to structural requirements, procedures, and
monitoring outcome. Treatment advice for individual head and neck cancer patients
is best discussed within a multidisciplinary team. Cisplatin is the drug of choice for
concomitant chemoradiotherapy in the primary and postoperative setting, and also a
main component of induction chemotherapy. However, acute and late toxicity is often
significant. Checkpoint inhibitors have recently been proven to be active in the metastatic
setting which has resulted in a shift of paradigm. Detailed knowledge, institution of
preventive measures, early recognition, and prompt treatment of adverse events during
systemic therapy is of paramount importance. Documentation of patient characteristics,
tumor characteristics, treatment details, and clinical and patient reported outcome is
essential for monitoring the quality of care. Participation in initiatives for accreditation and
registries for benchmarking institutional results are powerful incentives for implementation
of best practice procedures.
Keywords: best practice, systemic treatment, chemotherapy, immunotherapy, head and neck cancer, squamous
cell carcinoma
INTRODUCTION
Patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma
(HNSCC) constitute a challenging population for systemic treatment because of tumor related,
patient related and treatment related factors. The primary tumor can cause problems with eating,
dysphagia and pain, resulting in significant weight loss already before diagnosis, while weight loss of
more than 5% is an independent prognostic factor for worse progression free survival (1). Patients
with advanced hypopharyngeal and laryngeal carcinomas can present with airway obstruction, or
develop airway obstruction early during treatment and may require a tracheostomy. Patient related
factors that can complicate systemic treatment are tobacco and alcohol addiction, co-morbidity and
lack of a social network. In the curative setting, high-dose cisplatin concurrent with radiotherapy is
the standard of care, either as primary treatment or after surgery. Chemoradiotherapy induces high
rates of acute and late or long term adverse events. On the other hand, in the recurrent/metastatic
setting, the field is rapidly evolving with the emergence of immune checkpoint inhibitors. Here,
we summarize standard systemic treatment regimens, and describe best practice for administering
systemic treatment with regards to structural requirements, procedures and monitoring outcome.




For patients with locoregionally advanced HNSCC with non-
resectable tumors or in whom functional outcome of surgery is
expected to be poor, primary concomitant chemoradiotherapy
(CRT) with high-dose cisplatin (100 mg/m2) delivered every
3 weeks × 3 is the preferred treatment regimen (2–6). In
Table 1, treatment regimens based on at least one phase III study
are summarized. In oropharyngeal cancer patients accelerated
fractionation radiotherapy over 6 weeks with two cycles of
TABLE 1 | Standard systemic treatment regimens for HNSCC*.
Setting Regimen (reference) Dosing schedule Remarks
Induction chemotherapy Benefit over CRT is unclear
TPF (7) Docetaxel 75 mg/m2 + cisplatin 100 mg/m2 on day 1 followed by
continuous infusion of 5FU 1,000 mg/m2/day for 4 days every 3 weeks
for three cycles
US regimen
TPF (8, 9) Docetaxel 75 mg/m2 + cisplatin 75 mg/m2 on day 1 followed by




Cisplatin (4, 6, 10–12) Cisplatin 100 mg/m2 on day 1, 22, and 43 during standard
fractionated RT (or on day 1 and 22 during accelerated RT)
Preferred CRT regimen
Accelerated RT plus 2 cycles cisplatin was not
superior to standard fractionated RT plus three
cycles cisplatin
Carboplatin/5FU (13) Carboplatin 70 mg/m2 on day 1–4, continuous infusion of 5FU 600
mg/m2/day on day 1–4 in week 1, 4, and 7 during RT
Has not been compared head to head with cisplatin
Cetuximab (14) Cetuximab 400 mg/m2 1 week before start of RT and weekly 250
mg/m2 during RT
Inferior to cisplatin (for HPV related oropharyngeal
cancer)
Postoperative chemoradiotherapy
Cisplatin (15–18) Cisplatin 100 mg/m2 on day 1, 22, and 43 during RT
Cisplatin 50mg flat dose weekly
Inferior LRC with weekly 30 mg/m2 cisplatin
compared to 3-weekly 100 mg/m2
Superior LRC, OS and DFS with weekly 50mg
cisplatin compared to radiotherapy alone but has
not been compared to 3-weekly 100 mg/m2
Recurrent/metastatic palliative setting, 1st line
Pembrolizumab (19) Pembrolizumab 200mg every 3 weeks Approved by FDA but not (yet) by EMA
Superior OS compared to EXTREME in patients
with CPS ≥20 and in patients with CPS ≥1
Platinum, 5FU and
pembrolizumab (19)
Cisplatin 100 mg/m2 or carboplatin AUC 5 on day 1, plus 5FU 1,000
mg/m2/day on day 1–4, every 3 weeks for a maximum of six cycles
plus pembrolizumab 200mg every 3 weeks until progression
Approved by FDA but not (yet) by EMA
Superior OS compared to EXTREME
EXTREME (20) Cisplatin 100 mg/m2 or carboplatin AUC 5 on day 1, plus 5FU 1,000
mg/m2/day on day 1–4, every 3 weeks for a maximum of six cycles
plus cetuximab 400 mg/m2 at first dose, then 250 mg/m2 weekly until
disease progression
Recurrent/metastatic palliative setting, 2nd line
Nivolumab (21) Nivolumab 3 mg/kg (can be replaced by 240mg flat dose) every 2
weeks
After platinum containing chemotherapy
Pembrolizumab (22) Pembrolizumab 200mg every 3 weeks After platinum containing chemotherapy
Europe: restricted to patients with PD-L1 TPS
≥ 50%
*Based on at least one randomized phase III study. 5FU, 5-fluorouracil; AUC, area under the curve in mg per milliliter per minute; CPS, combined positive score for PD-L1 expression on
tumor and immune cells; CRT, chemoradiotherapy; DFS, disease free survival; EMA, European Medicines Agency; FDA, US Food and Drug Administration; LRC, locoregional control;
OS, overall survival; PD-L1, programmed death receptor ligand 1; RT, radiotherapy; TPF, docetaxel (Taxotere?), cisplatin (platinum), and 5FU; TPS, tumor proportion score (percentage
of tumor cells with membranous PD-L1 staining).
high-dose cisplatin resulted in similar outcome as conventional
fractionation radiotherapy over 7 weeks with three cycles of high-
dose cisplatin (10). Alternative concomitant systemic therapy
regimens that improve overall survival compared to radiotherapy
alone are carboplatin with infusional 5-fluorouracil (5FU) (13)
or cetuximab (14). Based upon a lower level of evidence weekly
cisplatin (40 mg/m2) (23–25), cisplatin with 5FU (26, 27),
hydroxyurea with 5FU, cisplatin with paclitaxel (26, 27), or
weekly carboplatin with paclitaxel can be considered (28). Benefit
of concomitant chemotherapy decreases with age, and in a meta-
analysis no benefit over locoregional treatment alone could be
demonstrated for patients≥70 years of age (29). Similarly, elderly
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patients do not benefit in the same way as younger patients from
the addition of cetuximab to radiotherapy (14). This is paralleled
by an increase in non-cancer related deaths in elderly patients.
Proper selection of fit elderly patients with geriatric assessment
might identify a subgroup that derives the same benefit as
younger patients, but prospective data to support this is currently
lacking. Treatment of elderly head and neck cancer patients has
recently been extensively reviewed (30). Hypoxia modification
with nimorazole during radiotherapy has been shown to
improve locoregional control compared to radiotherapy alone
(31) and is used in some countries as a standard of care.
Patients with locoregionally advanced human papilloma virus
(HPV) associated oropharyngeal cancer have significantly better
outcome than patients with non-HPV related HNSCC, and
treatment de-intensification strategies are under investigation.
However, two randomized studies recently demonstrated that
radiotherapy with cetuximab results in inferior overall survival
compared to CRT with high-dose cisplatin, which therefore
remains the standard of care (11, 12).
Patients who undergo primary surgical treatment and have
involved resectionmargins and/or extranodal extension of lymph
node metastasis are at high risk of developing recurrent disease.
Outcome in these patients is improved by the addition of
concomitant high-dose cisplatin to postoperative radiotherapy
(15, 16, 32). Results of studies with high-dose and low-dose
concurrent cisplatin were recently summarized (33). Of the
two randomized trials that have been reported, one study was
not evaluable for efficacy due poor accrual (34). The second
study compared 6–7 weekly cycles of 30 mg/m2 with three
cycles of 100 mg/m2 cisplatin every 3 weeks (17). Locoregional
control at 2 years was inferior in the low-dose arm (58.5
vs. 73.1%) and progression free survival and overall survival
were numerically inferior but statistical significance was not
reached for survival endpoints. It remains unclear to what
extend the lower cumulative dose of the weekly regimen is
responsible for inferior efficacy. Results of a third randomized
phase II/III study comparing three times 100 mg/m2 with 7
weekly cycles of 40 mg/m2 cisplatin in the postoperative setting
are awaited (35).
Induction chemotherapy followed by either radiotherapy
alone, or radiotherapy with cetuximab, or CRT with weekly
carboplatin, can be used as an organ preservation strategy.
However, its benefit over CRT alone is not clear at this
stage with conflicting phase III studies and heterogenous
patient populations on these trials and the role of induction
chemotherapy is therefore debated (36, 37). If induction
chemotherapy is chosen, docetaxel with cisplatin and 5FU (TPF)
is the preferred combination (7–9). In the United States (US)
three cycles of docetaxel 75 mg/m2 plus cisplatin 100 mg/m2
followed by continuous infusion of 1,000 mg/m2 5FU for 4 days
every 3 weeks is used (7), while in Europe four 3-weekly cycles of
docetaxel 75 mg/m2, cisplatin 75 mg/m2 followed by continuous
infusion of 750 mg/m2 5FU for 5 days is used (8).
Recurrent/Metastatic Disease
For patients with metastatic HNSCC, or recurrent disease that
is not amenable to curative intent treatment, the EXTREME
regimen consisting of cisplatin or carboplatin with 5FU and
cetuximab followed by cetuximab maintenance has been the
standard first-line treatment for the last decade (20). Based upon
a lower level of evidence, other chemotherapy combinations
or single-agent treatment options can be considered (2). In
patients who progress after platinum containing chemotherapy,
treatment with an anti-programmed death 1 (PD1) antibody
improves overall survival and induces durable responses in a
subgroup of patients with a lower rate of grade 3–4 adverse
events compared to investigator’s choice systemic therapy (21,
22, 38, 39). Nivolumab was shown to improve overall survival
irrespective of HPV status or programmed death ligand 1
(PD-L1) expression with better preservation of quality of life
compared to the control arm (38, 40). Pembrolizumab also
improved overall survival, in the entire cohort and in the
subgroups of patients with PD-L1 positive tumors (22). This led
to approval of pembrolizumab for patients with a PD-L1 tumor
proportion score (percentage of tumor cells with membranous
PD-L1 staining) ≥50% in 2018 by the European Medicines
Agency (EMA), while the FDA granted accelerated approval
irrespective of PD-L1 expression back in 2016, based on the
results of the phase 1b study (41). However, treatment paradigm
for the recurrent/metastatic setting will likely change again soon,
since the final analysis of the KEYNOTE 048 study in the first-
line recurrent/metastatic setting indicated that compared with
the EXTREME regimen, pembrolizumab plus platinum and 5FU
followed by pembrolizumab maintenance had superior overall
survival in the PD-L1 combined positive score (CPS) ≥20,
CPS ≥1, and total populations with comparable safety (19).
Pembrolizumab alone had superior overall survival in the CPS
≥20 and≥1 populations, with non-inferior overall survival in the
total population, and favorable safety compared to EXTREME
(19) and is already mentioned in the NCCN clinical practice
guideline (2).
STRUCTURAL REQUIREMENTS
The first requirement for effective delivery of systemic therapy to
HNSCC patients is identification of patients in whom systemic
treatment is indicated. The best way of doing this is discussing
every newly diagnosed patient, every patient with recurrent
disease and every patient who requires a change in treatment
plan, during a multidisciplinary team (MDT) conference. An
MDT approach is associated with improved tumor staging,
better adherence to quality indicators, more concomitant CRT,
shorter time between surgery and adjuvant therapy, higher
completion rate of adjuvant treatment, and most important:
improved disease specific and overall survival (42–46). According
to the Dutch guidelines, a head and neck oncology center
should at minimum have in the team three head and neck
surgeons (at least one otolaryngeal surgeon and one oral and
maxillofacial surgeon), two reconstructive surgeons, two head
and neck radiation oncologists, and at least one head and neck
medical oncologist, dermatologist, head and neck radiologist,
pathologist, nuclear medicine physician, oncology nurse/case
manager, dietician, physiotherapist, speech-language pathologist,
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dentist-maxillofacial prosthodontist, psychologist, and social
worker (47). This list closely resembles the core team defined in
the Canadian guidelines (48, 49). The minimum recommended
volume for medical oncologists who care for head and neck
cancer patients is 25 per year, although scientific evidence to
support this number is lacking (48–50). In the Netherlands, the
minimum required volume for immunotherapy in a hospital is
20 patients per year, but this may include different cancer types.
With regards to the healthcare facility, the optimal situation is
to have the pharmacy, the infusion facility, the radiation center,
the inpatient ward, specialists for treatment of immunotherapy
side effects, an intensive care unit, and a 24/7 emergency
department in one center. This enables quick communication
between health care professionals and prompt admission to
address adverse events, which helps to keep treatment breaks to
a minimum.
Specific information about treatment schedules, potential side
effects, instructions on when to contact the oncology nurse or
medical oncologist along with contact details, is of importance
for patients. This can be digital or on paper.
BEST PRACTICE PROCEDURES
After discussing a patient within the MDT, it is recommended
to file a report in the patient’s records which accessible for
every teammember and contains tumor characteristics including
TNM stage, patient characteristics such as co-morbidity, medical
history, tobacco and alcohol consumption, treatment intent
(curative or palliative), and treatment plan (50). If the treatment
advice deviates from the guidelines, it is preferable to specify the
reason for it.
A longer waiting time between histopathological diagnosis
and start of primary treatment is independently associated with
worse overall survival in patients with HNSCC (51). The median
tumor volume doubling time was shown to be 99 days in a Danish
cohort, but in the half with the fastest growing tumors this was 30
days (52). Therefore, starting treatment as quickly as possible will
improve patient outcome.
If systemic therapy is recommended by the MDT, the
patient is referred to the medical oncologist who will carefully
evaluate if systemic treatment is feasible through assessing the
performance status, co-morbidity, previous medical history,
organ function, and current medication. For elderly patients,
geriatric screening and/or comprehensive geriatric assessment is
recommended (53). Vulnerability according to the G8 was found
to be independently associated with worse overall survival and
persistent lower quality of life in HNSCC patients who received
curative intent (chemo)radiotherapy (54).
Chemotherapy
In general, Eastern Cooperative Oncology Group (ECOG)
performance status worse than 2 (where 2 is defined as
ambulatory and able of all self-care but unable to carry out any
work activities; up and about for >50% of waking hours) is
considered a contraindication for chemotherapy. Furthermore,
blood cell counts, renal function, electrolytes and liver tests need
to be adequate, and have to be assessed before each cycle.
Nutritional status is of particular importance in HNSCC
patients. The tumor itself can cause problems with chewing,
odynophagia, and dysphagia which can result in malnutrition.
In addition, tooth extractions are performed in many patients
before start of radiotherapy, further limiting the ability to eat
normally. Also treatment side effects, especially of concomitant
CRT, can cause swallowing problems. In the acute phase this
is mainly related to mucositis, while dry mouth and sticky
saliva are prominent long term side effects. In order to secure
nutrition during CRT, prophylactic placement of a percutaneous
endoscopic gastrostomy (PEG) tube can be considered. In a
randomized study prophylactic PEG tube placement resulted
in less malnourished patients, longer enteral feeding and better
quality of life at 6 months after treatment without increased
risk of long-term dysphagia compared with a control group
treated according to clinical practice (55, 56). However, not
all patients need enteral feeding, and selection of patients at
high risk for malnutrition based on weight loss before start
of treatment, age and radiotherapy dose to the constrictor
muscles, can be used to select patients for prophylactic PEG
tube placement (57). Nasogastric tube feeding appears to be an
effective alternative to maintain body weight and the optimal
method for enteral feeding of HNSCC patients has not yet been
determined (58).
It is recommended to dose chemotherapy on actual body
weight or, in the case of carboplatin, on actual stable creatinine
clearance. In order to check and sign that the right drug is given
to the right patient at the right dose at the right moment, the
pharmacist and the nurses at the infusion facility need to be
informed which treatment protocol applies, what is the treatment
cycle number and day, the date, the height of the patient,
actual weight, body surface area and/or creatinine clearance,
and whether or not a dose reduction is applied. Including this
information in the prescription, and filing prescriptions in the
patient records facilitates personalized treatment modifications.
Nausea is a prominent side effect of chemotherapy and
cisplatin belongs to the high-emetic-risk antineoplastic agents. A
combination of four drugs consisting of a neurokinin 1 receptor
antagonist, a serotonin receptor antagonist, dexamethasone,
and olanzapine is recommended for cisplatin (59). Carboplatin
belongs to the moderate-emetic-risk category requiring a three-
drug antiemetic regimen, and docetaxel, 5FU and cetuximab have
a low-emetic-risk, however combinations andmultiday regimens
should be treated per day for the drug with the highest emetic
risk, and for 2 days after the last dose (59).
In addition to general chemotherapy side effects, cisplatin
can cause renal toxicity, hearing loss, and neuropathy, and
it can provoke cardiovascular events. Therefore, audiometric
testing and an electrocardiogram is recommended before start
of treatment, and thereafter if clinically indicated. Before
every cycle, presence of neuropathy has to be assessed
and creatinine clearance should be ≥60 ml/min. Adequate
intravenous hydration from 2 to 12 h prior until at minimum
6h after the administration of cisplatin is essential to protect
renal function, and forced diuresis with mannitol or diuretics
may be required (60). Allergic reactions to platinum compounds
can occur. Therefore, it is important to have medication and a
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protocol for treatment of allergic reactions readily available at the
infusion facility.
5FU is degraded into inactive metabolites by the enzyme
dihydropyrimidine dehydrogenase (DPD). Variations in the gene
encoding DPD result in reduced enzyme activity, increased
5FU exposure and severe mucositis and hematologic toxicity.
Prospective genotyping and upfront 5FU dose reduction in
patients who carry a variant allele predicting reducedmetabolism
can prevent potentially lethal toxicity also in patients who
undergo chemoradiation with a relatively low 5FU dose (61, 62).
In intermediate metabolizers, a dose reduction of 25–50% is
recommended, while in poor metabolizers with complete DPD
deficiency, it is recommended to avoid 5FU (63).
Docetaxel can induce fluid retention and hypersensitivity
reactions characterized by generalized erythema and
hypotension. In order to reduce the risk and severity of
these side effects, patients can to be treated with dexamethasone
for 3 days, starting the night before docetaxel administration
(64). A study in Chinese patients with head and neck cancer
receiving TPF showed that lower dexamethasone doses than
the recommended six doses of 8mg (twice daily) did not
increase the risk of severe hypersensitivity reactions (65).
The risk of alopecia from docetaxel can be reduced by scalp
cooling (66). However, because of tumor localization close
to the scalp, reduced efficacy as a result of cooling is a
concern and therefore scalp cooling is not recommended in
HNSCC patients. For the TPF regimen, antibiotic prophylaxis
with ciproflacin 500mg orally twice daily, from day 5 to 15
for prevention of neutropenic infections was administered
in the pivotal trial (8). If patients develop neutropenic
fever or neutropenic infection, addition of granulocyte
colony stimulating factor (G-CSF) after the next cycles is
recommended (67). In a retrospective analysis, primary
prophylactic G-CSF did not reduce the incidence of febrile
neutropenia in patients treated with TPF and ciprofloxacin
or levofloxacin (68). Like for cisplatin, neuropathy is also a
frequent side effect of docetaxel and assessment before each cycle
is recommended.
Cetuximab
Cetuximab can induce severe infusion-related reactions,
including anaphylactic reactions even within minutes of the start
of the first infusion. In the registration study, an antihistamine
was administered as premedication, followed by a test dose of
20mg cetuximab in 10min followed by 30min of observation
(69). Four out of 211 patients discontinued cetuximab because
of a hypersentitivity reaction after the test dose or the first dose.
The compendium advises premedication with an antihistamine
and a steroid, as well as close monitoring and prompt treatment
of allergic reactions (70). A frequent adverse event of EGFR
targeting drugs is an acneiform skin rash. Prophylactic treatment
with an oral antibiotic such as doxycycline or minocycline can
be used to reduce the severity of the rash, although not all
trials showed consistent results, however it is recommended
to instruct patients about sunlight protection (71). Another
frequently occurring side effect is hypomagnesemia, especially
in patients who receive ≥7 cetuximab infusions and concurrent
cisplatin or carboplatin (72). Intravenous supplementation may
be required and it may take several weeks or months to resolve.
Immune Checkpoint Inhibitors
Nivolumab, pembrolizumab, and other immune checkpoint
inhibitors can cause a wide spectrum of immune related adverse
events. The most frequently affected organs are the skin, the
gastrointestinal tract, the lungs, and endocrine organs including
thyroid, pituitary, and adrenal glands. Less commonly the
musculoskeletal tract, nervous system, kidneys, eyes, and heart
and blood vessels are affected. Some of these side effects are
potentially lethal. Prompt treatment usually results in complete
resolution, although endocrinopathies may require lifelong
hormonal substitution. The European Society of Medical
Oncology (ESMO) and the American Society of Clinical
Oncology (ASCO) developed guidelines for management of
immunotherapy side effects (73, 74). For grade 3–4 toxicity,
consultation of organ specialists such as a dermatologist,
gastroenterologist, endocrinologist, pulmonologist etc. is
required, which implies that a multidisciplinary team with
expertise in treatment of immunotherapy side effects has to
be available. In contrast to chemotherapy and cetuximab,
immune checkpoint inhibitors may be continued at first
progression provided that the patient has not deteriorated,
although the incidence of pseudoprogression appears to be low
in HNSCC (75).
OUTCOME
If there is suspicion of recurrent disease in patients treated
with curative intent, imaging and biopsy is required for
confirmation. In the palliative setting, assessment of disease
progression and treatment response according to the Response
Evaluation Criteria In Solid Tumors (RECIST) (76) is preferred,
also for patients treated outside studies. For evaluation
of immunotherapy, a consensus guideline called iRECIST
has been developed to capture response patterns such as
pseudoprogression that differ from response patterns to
cytotoxic agents (77). Universal criteria for evaluation facilitate
benchmarking of institutional results against data from other
centers and comparison with the literature. For the same reason
it is important to record the date of death and whenever possible,
the cause of death in the patient file.
Documentation of complications, unexpected toxicity and
serious toxicity of systemic treatment can improve safety of
the individual patient, and prevent further damage. It also
allows listing for periodical discussion of incidence and potential
causes within the MDT. When these discussions are followed by
implementation of strategies to lower complication risk, future
patients will be better protected. In order to be able to compare
incidence of severe toxicity and complications with the literature
and with other centers, use of the Common Terminology Criteria
for Adverse Events is recommended (78).
Next to medical outcome parameters, patient reported
outcome measures (PROMs) are increasingly used to get insight
in the impact of treatment on disease symptoms, functional
ability, and quality of life (79, 80).
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FIGURE 1 | Infographic representing best practice structural requirements, procedures, and outcome evaluation for systemic treatment of head and neck squamous
cell carcinoma patients, and how quality can be assessed.
QUALITY ASSESSMENT
Several accreditation or certification programs have been
launched with the aim to improve the quality of care for
cancer patients. An example is ASCO’s Quality Oncology
Practice Initiative (QOPI)1. Next to a core module and a
symptom/toxicity module, tumor specific modules have been
developed, although not yet for head and neck cancer. To
illustrate, one of the core module measures is that height, weight,
and body surface area should be documented prior to curative
chemotherapy. The Organization of European Cancer Institutes
(OESI) has created an accreditation and designation program
for Clinical Cancer Centers and Comprehensive Cancer Centers
which is based on peer review2. Participation in such initiatives
can help centers to identify and improve evidence based quality
indicators (Figure 1). Accreditation programs aremainly focused
on structural and procedural quality indicators. Monitoring with
benchmarking of outcome parameters is a powerful incentive
for implementing best practice procedures, but challenging to
achieve, for instance because case mix variability has to be taken
into account. Increasingly, national registries of real world data
are set up and used for monitoring and improving quality of care
(81). The Dutch Head and Neck Audit (DHNA) is a registry that
was recently launched and covers a broad spectrum of structural,
procedural, and outcome parameters. Participation is mandatory
1https://practice.asco.org/quality-improvement/quality-programs/quality-
oncology-practice-initiative (accessed on February 10, 2019).
2http://www.oeci.eu/Accreditation/Page.aspx?name=BACKGROUND (accessed
on February 10, 2019).
for head and neck cancer centers, and the first results show
that even in a small country with centralized head and neck
cancer care, variation exists in quality indicators (82). Results
of individual centers participating in the DHNA will become
publicly available in the next years to maximize transparency
and to boost initiatives for implementation of best practice
procedures. The registration burden of such initiatives will
hopefully decrease in the near future with advanced information
technology and registration at the source. Potential draw backs
of public availability of institutional results include a risk
that institutes will primarily accept low risk patients and that
insurance companies may choose to cover costs only in the best
performing centers.
In summary, best practice in systemic therapy for HNSCC
involves participation in an MDT and following guidelines.
It requires detailed knowledge and anticipation of side effects
of systemic therapy and expertise in management of this
patient population. Documentation of patient characteristics,
tumor characteristics, treatment details, and clinical and patient
reported outcome is essential for monitoring the quality of care.
Participation in initiatives for accreditation and registries for
benchmarking institutional results can empower initiatives for
implementation of best practice procedures.
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